The Claim
In individuals with autosomal dominant Alzheimer’s disease, cerebrospinal fluid and plasma neurofilament light chain levels rise similarly during the presymptomatic phase, beginning 10–20 years before estimated symptom onset, and both are associated with subsequent gray matter atrophy, but plasma levels plateau after symptom onset while cerebrospinal fluid levels continue to rise, indicating that cerebrospinal fluid neurofilament light chain is a more sensitive marker of ongoing neurodegeneration in symptomatic stages.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In people with inherited Alzheimer’s disease, levels of neurofilament light chain in cerebrospinal fluid and blood increase together 10 to 20 years before symptoms appear and both correlate with loss of brain gray matter. After symptoms begin, blood levels stabilize but cerebrospinal fluid levels keep rising, showing that cerebrospinal fluid neurofilament light chain more accurately reflects ongoing nerve cell damage during the symptomatic phase.
See the scientific wording
In individuals with autosomal dominant Alzheimer’s disease, cerebrospinal fluid and plasma neurofilament light chain levels rise similarly during the presymptomatic phase, beginning 10–20 years before estimated symptom onset, and both are associated with subsequent gray matter atrophy, but plasma levels plateau after symptom onset while CSF levels continue to rise, suggesting CSF NfL is a more sensitive marker of ongoing neurodegeneration in symptomatic stages.
When nerve fibers in the brain break down due to disease, they release a protein called neurofilament light chain into the fluid surrounding the brain. This protein flows into the spinal fluid and also crosses into the bloodstream. In early stages, both fluids show rising levels of the protein as damage increases. Later, when symptoms appear, the brain keeps releasing more of the protein, but the bloodstream stops showing higher levels because the body clears it less efficiently from the brain to the blood.
What the research says
1 studyIn people with a rare inherited form of Alzheimer’s, both blood and spinal fluid show a rise in a nerve damage marker 10–20 years before symptoms. But after symptoms start, spinal fluid levels keep climbing while blood levels stop — so spinal fluid is a better way to track worsening damage later on.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.